Bristol-Myers Squibb Company in 3 stories
The narratives BMY currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
BMY in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
External Chinese assets offer a relatively rapid way to address patent expirations and pipeline gaps.
Bear side
2 stories- America Imports the World's Drug Prices
BMY in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Lower realized prices would compound the pressure from looming patent expirations across its mature blockbuster portfolio.
- The Patent Cliff Sparks a Biotech Land Grab
BMY in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Bristol Myers faces overlapping exclusivity losses across major products, increasing pressure to acquire growth at potentially expensive valuations.